Coverage-gated living condition brief

Breast Cancer peptide evidence brief

A cited Breast Cancer peptide evidence brief across 26 exact-label ClinicalTrials.gov records, 7 connected profiles, and 14 registry-update years. The label is copied from each retained registry version and does not imply that PeptideScanner has verified a diagnosis, treatment relationship, or study result.

Registry records

26 selected records.

Connected peptides

7 profiles.

Registry update years

2012–2026 in selected records.

Direct collection answer · published August 17, 2026

What peptide evidence does PeptideScanner carry for Breast Cancer?

PeptideScanner’s selected collection contains 26 retained ClinicalTrials.gov records carrying the exact condition label “Breast Cancer,” connected to 7 peptide profiles across 14 registry-update years.

That answer describes this collection and the exact cited registry observations below. It is not a conclusion about whether any peptide treats Breast Cancer, and it is not a safety or efficacy assessment.

Indication intelligence

Selected evidence landscape

Trial phases4

Phase labels copied from the retained ClinicalTrials.gov versions.

Registry statuses4

Overall statuses at each retained observation, not necessarily current today.

Across the connected peptide profiles, PeptideScanner also carries 268 selected PubMed records and 72 selected Drugs@FDA applications. Those records are profile context only; PeptideScanner does not claim they concern Breast Cancer unless their own cited source says so.

Related profile context

Literature connected through these peptide profiles

All literature facets →

This is a bounded sample of up to six PubMed bibliography records connected through peptide profiles on this hub, not the total profile literature count above. They are not condition-matched records, and their presence does not establish that they concern Breast Cancer.

Goserelin · source record 2026-08-13

Roles of Goserelin in Gynecological Disorders.

PubMed lists PMID 42226753 in Drug design, development and therapy as Journal Article, Review, with publication-date metadata of 2026-05-27 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Open attributed literature record →

Triptorelin · source record 2026-11-09

Comparison of dienogest versus triptorelin acetate in premenopausal women with adenomyosis: a prospective clinical trial.

PubMed lists PMID 25990480 in Archives of gynecology and obstetrics as Clinical Trial, Comparative Study, Journal Article, with publication-date metadata of 2015-05-20 (day precision). PeptideScanner associated the retained record with the identity slug triptorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Open attributed literature record →

Leuprolide · source record 2026-11-06

Leuprolide acetate, a GnRH agonist, preserves cerebellar integrity and motor coordination in a rat model of hepatic encephalopathy.

PubMed lists PMID 42962871 in Physiology & behavior as Journal Article, with publication-date metadata of 2026-10-30 (day precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Open attributed literature record →

Desmopressin · source record 2026-10-29

Diagnostic accuracy of bilateral inferior petrosal sinus sampling using desmopressin or corticotropic- releasing hormone in ACTH-dependent Cushing's syndrome: A systematic review and meta-analysis.

PubMed lists PMID 35478451 in Reviews in endocrine & metabolic disorders as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2022-04-28 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Open attributed literature record →

Pasireotide · source record 2026-10-31

Pasireotide-LAR and pegvisomant combination in resistant acromegaly: a case series of predominantly mammosomatotroph adenomas.

PubMed lists PMID 42778805 in Pituitary as Journal Article, with publication-date metadata of 2026-09-23 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Open attributed literature record →

Thymosin alpha-1 · source record 2026-09-29

Clinical Applications and Evidence Landscape of Thymosin Alpha 1 as an Immunomodulatory Adjunct in Cancer Care: A Scoping Review.

PubMed lists PMID 42797537 in Pharmaceuticals (Basel, Switzerland) as Journal Article, Review, with publication-date metadata of 2026-09-19 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Open attributed literature record →

Collection change ledger

Recently changed records on this condition hub

All recent changes →

These events come only from the exact registry records shown on this page. The condition label does not establish a diagnosis, treatment relationship, or scientific agreement.

Record added

ClinicalTrials.gov record NCT01606072

PeptideScanner retained ClinicalTrials.gov record NCT01606072 at 2026-11-16T01:33:21.554Z. Its registry update date was 2015-08-28, and PeptideScanner's reviewed identity mapping was desmopressin.

PeptideScanner change date
November 16, 2026
Cited source date
August 28, 2015
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00066703

PeptideScanner retained ClinicalTrials.gov record NCT00066703 at 2026-11-15T21:49:16.513Z. Its registry update date was 2026-02-06, and PeptideScanner's reviewed identity mapping was triptorelin.

PeptideScanner change date
November 15, 2026
Cited source date
February 6, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00186121

PeptideScanner retained ClinicalTrials.gov record NCT00186121 at 2026-11-15T21:50:32.222Z. Its registry update date was 2019-10-07, and PeptideScanner's reviewed identity mapping was goserelin.

PeptideScanner change date
November 15, 2026
Cited source date
October 7, 2019
Evidence lane
Clinical trials

Exact-record source chronology

Breast Cancer registry timeline

All trial facets →

Years come from the last-update date on each retained ClinicalTrials.gov observation. They show source chronology, not when PeptideScanner added the record and not a continuous monitoring guarantee.

2026

8 records

2025

1 record

2024

3 records

2023

1 record

2022

1 record

2021

1 record

2020

1 record

2019

1 record

2018

1 record

2017

1 record

2016

2 records

2015

1 record

2013

3 records

2012

1 record
What this brief cannot answer